How the tumor environment fuels early pancreatic cancer
Tumor Microenvironment Crosstalk Drives Early Lesions in Pancreatic Cancer
Researchers are exploring how cells and supporting tissue around early pancreatic lesions communicate so doctors can find and stop pancreatic cancer sooner.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11173891 on NIH RePORTER |
What this research studies
This center brings together teams at several major hospitals to study the very earliest changes that lead to pancreatic cancer. They focus on precursor lesions called PanINs and IPMNs and the nearby cells (including fibroblasts) that form a precursor microenvironment. The work uses patient samples, 3-D models, and animal studies to see how signals between cells promote lesion growth. The goal is to turn those findings into better early detection methods and ways to block progression to invasive cancer.
Who could benefit from this research
Good fit: Ideal candidates would include people with pancreatic cysts or known precursor lesions (IPMNs or suspected PanINs), those with a strong family history, or individuals with high genetic risk for pancreatic cancer.
Not a fit: People with advanced, metastatic pancreatic cancer are unlikely to gain direct benefit from this early-detection–focused work.
Why it matters
Potential benefit: If successful, the work could enable earlier detection and new strategies to intercept pancreatic cancer before it becomes deadly.
How similar studies have performed: Previous research has described the genetics of precursor lesions and suggested the microenvironment matters, but translating that into reliable early detection or interception is still largely experimental.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Maitra, Anirban — New York University School of Medicine
- Study coordinator: Maitra, Anirban
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.